Literature DB >> 23877683

Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.

Gulsen Hazirolan1, Emilia Canton, Selma Sahin, Sevtap Arikan-Akdagli.   

Abstract

Treatment of disseminated Trichosporon infections still remains difficult. Amphotericin B frequently displays inadequate fungicidal activity and echinocandins have no meaningful antifungal effect against this genus. Triazoles are currently the drugs of choice for the treatment of Trichosporon infections. This study evaluates the inhibitory and fungicidal activities of five triazoles against 90 clinical isolates of Trichosporon asahii. MICs (μg/ml) were determined according to Clinical and Laboratory Standards Institute microdilution method M27-A3 at 24 and 48 h using two endpoints, MIC-2 and MIC-0 (the lowest concentrations that inhibited ∼50 and 100% of growth, respectively). Minimum fungicidal concentrations (MFCs; μg/ml) were determined by seeding 100 μl of all clear MIC wells (using an inoculum of 10(4) CFU/ml) onto Sabouraud dextrose agar. Time-kill curves were assayed against four clinical T. asahii isolates and the T. asahii ATCC 201110 strain. The MIC-2 (∼50% reduction in turbidity compared to the growth control well)/MIC-0 (complete inhibition of growth)/MFC values that inhibited 90% of isolates at 48 h were, respectively, 8/32/64 μg/ml for fluconazole, 1/2/8 μg/ml for itraconazole, 0.12/0.5/2 μg/ml for voriconazole, 0.5/2/4 μg/ml for posaconazole, and 0.25/1/4 μg/ml for isavuconazole. The MIC-0 endpoints yielded more consistent MIC results, which remained mostly unchanged when extending the incubation to 48 h (98 to 100% agreement with 24-h values) and are easier to interpret. Based on the time-kill experiments, none of the drugs reached the fungicidal endpoint (99.9% killing), killing activity being shown but at concentrations not reached in serum. Statistical analysis revealed that killing rates are dose and antifungal dependent. The lowest concentration at which killing activity begins was for voriconazole, and the highest was for fluconazole. These results suggest that azoles display fungistatic activity and lack fungicidal effect against T. asahii. By rank order, the most active triazole is voriconazole, followed by itraconazoleposaconazoleisavuconazole > fluconazole.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23877683      PMCID: PMC3811412          DOI: 10.1128/AAC.00850-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  In vitro antifungal susceptibilities of Trichosporon species.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 2.  Infections due to emerging and uncommon medically important fungal pathogens.

Authors:  T J Walsh; A Groll; J Hiemenz; R Fleming; E Roilides; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

Review 3.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

4.  Contributions to a revision of the genus Trichosporon.

Authors:  E Guého; M T Smith; G S de Hoog; G Billon-Grand; R Christen; W H Batenburg-van der Vegte
Journal:  Antonie Van Leeuwenhoek       Date:  1992-05       Impact factor: 2.271

5.  Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients.

Authors:  Ayse Kalkanci; Takashi Sugita; Sevtap Arikan; Mine Yucesoy; Beyza Ener; Feza Otag; Nuri Kiraz; Semra Kustimur; Banu Sancak; Canan Evci; Gurol Emektas
Journal:  Med Mycol       Date:  2010-02       Impact factor: 4.076

Review 6.  Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.

Authors:  O A Cornely
Journal:  Infection       Date:  2008-07-19       Impact factor: 3.553

Review 7.  Update on the genus Trichosporon.

Authors:  Thomas C Chagas-Neto; Guilherme M Chaves; Arnaldo L Colombo
Journal:  Mycopathologia       Date:  2008-06-21       Impact factor: 2.574

8.  Susceptibility patterns and molecular identification of Trichosporon species.

Authors:  Juan L Rodriguez-Tudela; Teresa M Diaz-Guerra; Emilia Mellado; Virginia Cano; Cecilia Tapia; Alexander Perkins; Alicia Gomez-Lopez; Laura Rodero; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

9.  Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.

Authors:  John E Conte; Jeffrey A Golden; Gopal Krishna; Marina McIver; Emily Little; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

10.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

View more
  12 in total

1.  Amphiphilic Tobramycin Analogues as Antibacterial and Antifungal Agents.

Authors:  Sanjib K Shrestha; Marina Y Fosso; Keith D Green; Sylvie Garneau-Tsodikova
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

2.  Trichosporon loubieri Fungemia in a 39-Year-Old Caucasian Woman With B-Cell Lymphoblastic Leukemia.

Authors:  Archana Bhaskaran; Karam M Obeid; Sophie Arbefeville; Patricia Ferrieri
Journal:  Lab Med       Date:  2016-08

3.  Emerging Trichosporon asahii in elderly patients: epidemiological and molecular analysis by the DiversiLab system.

Authors:  M Treviño; C García-Riestra; P Areses; X García; D Navarro; F J Suárez; I A López-Dequidt; O Zaragoza; M Cuenca-Estrella
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-10       Impact factor: 3.267

4.  Trichosporon faecale invasive infection in a patient with severe aplastic anemia: Efficacy of voriconazole and liposomal amphotericin B before neutrophil recovery.

Authors:  Baptiste Pérard; Amandine Rougeron; Simon Favre; Isabelle Accoceberry; Stéphane Vigouroux; Catherine Mohr; Noël Milpied
Journal:  Med Mycol Case Rep       Date:  2015-07-02

5.  Multiple species of Trichosporon produce biofilms highly resistant to triazoles and amphotericin B.

Authors:  Isabel Antonieta Iturrieta-González; Ana Carolina Barbosa Padovan; Fernando César Bizerra; Rosane Christine Hahn; Arnaldo Lopes Colombo
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

6.  A fatal case of Trichosporon asahii fungemia and pneumonia in a kidney transplant recipient during caspofungin treatment.

Authors:  Mei-Fang Yang; Hai-Nv Gao; Lan-Juan Li
Journal:  Ther Clin Risk Manag       Date:  2014-09-30       Impact factor: 2.423

Review 7.  Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen.

Authors:  João N de Almeida Júnior; Christophe Hennequin
Journal:  Front Microbiol       Date:  2016-10-17       Impact factor: 5.640

Review 8.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

Review 9.  Rare fungal infectious agents: a lurking enemy.

Authors:  Anna Skiada; Ioannis Pavleas; Maria Drogari-Apiranthitou
Journal:  F1000Res       Date:  2017-10-31

10.  Antifungal susceptibility of non-albicans Candida spp. isolated from raw milk and human blood in Alborz and Tehran provinces.

Authors:  Zahra Namvar; Abbas Akhavan Sepahy; Robab Rafiei Tabatabaei; Sassan Rezaie
Journal:  Iran J Microbiol       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.